ViewMind is the global leader in precision measurement of neurocognitive health based on ocular digital phenotyping. ViewMind's extremely high sensitivity and specificity using context aware AI and digital brain assessments can contribute to advancing the field of neurological drug development and precision care.
Employees: 11-50
Investors 2
| Date | Name | Website |
| - | Wealthing ... | wealthing.... |
| - | Verge Heal... | verge.fund... |
Mentions in press and media 11
| Date | Title | Description |
| 10.12.2024 | ViewMind Joins Bio-Hermes-002 Landmark Study in Partnership with Global Alzheimer’s Platform Foundation | ViewMind Precision Neurological Assessments ViewMind Digital Biomarker To Enhance Alzheimer’s Diagnosis Through Diverse Biomarker Analysis We expect ViewMind’s promising technology to offer the field alternative methods for detecting and di... |
| 11.09.2024 | Bridging the Gap: Innovations in Patient Access and Affordability | In the evolving landscape of healthcare, patient access and affordability stand as towering challenges. The journey to obtain medications can feel like navigating a labyrinth. Many patients find themselves lost in a maze of bureaucracy, cos... |
| 09.09.2024 | New Episode of Advancements Airing on Saturday, September 14th at 8:00 pm ET | Advancements broadcast Watch to discover how technology and innovation are beckoning change. JUPITER, Fla., Sept. 9, 2024 /PRNewswire-PRWeb/ -- Tune in to Bloomberg on Saturday, September 14, 2024, to watch a new episode of Advancements, ho... |
| 27.07.2024 | The Future of Brain Health: ViewMind's Revolutionary Approach | In the realm of healthcare, innovation is the lifeblood that keeps the industry vibrant. Enter ViewMind, a company that has recently captured the spotlight by winning the 2024 North American Technology Innovation Leadership Award from Frost... |
| 23.07.2024 | ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution | ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling universal, language-free usage for fast and accurate results. SAN ANTONIO, July 23, 2024 /PRNews... |
| 04.04.2024 | ViewMind Inc. Joins NVIDIA Inception | ViewMind Joins as an NVIDIA Inception Partner ViewMind logo ViewMind Precision Neurological Assessments SAN FRANCISCO, CALIFORNIA, USA, April 4, 2024 /EINPresswire.com/ -- ViewMind Inc. today announced it has joined NVIDIA Inception, a prog... |
| 10.05.2023 | Scarlett Chen from Verge HealthTech Fund joins ViewMind’s board of directors | NEW YORK, NEW YORK, USA, May 10, 2023/EINPresswire.com/ -- Scarlett Chen from Verge HealthTech Fund joins ViewMind’s board of directors ViewMind today announced Scarlett Sijia Chen, Managing Partner of Verge HealthTech Fund, has been electe... |
| 27.04.2023 | ViewMind addresses healthcare inequities and disparities in dementia research and clinical work in Colombia, S. America | ViewMind addresses healthcare inequities and disparities in dementia research and clinical work NEW YORK, NEW YORK, USA, April 27, 2023/EINPresswire.com/ -- A significant barrier to dementia prevention, care and cure emerges from insufficie... |
| 25.08.2022 | Neurocognitive disease management leader, ViewMind Inc., announces the opening of ViewMind Labs | ViewMind Digital Biomarker Mother and son dealing with Alzheimer concerns The Neuroscience Group of the University of Antioquia, Colombia has become the location for the first global ViewMind Labs. One of the most important areas in the fig... |
| 20.07.2022 | Convincing Evidence of New Markers to Identify the Earliest Signs of Alzheimer’s | New Cognitive Biomarker detects specific neurocognitive features of dementia years before traditional forms of assessment NEW YORK, NEW YORK, USA, July 20, 2022 /EINPresswire.com/ -- Convincing Evidence of New Markers to Identify the Earlie... |
Show more